HLVX

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-60.1K ExitQ3 2025 $60k $2.09 $2.09
Jim SimonsRenaissance Technologies $-107.7K ExitQ3 2025 $108k $2.09 $2.09
Jim SimonsRenaissance Technologies $67.6K AddQ2 2025 $68k $1.82 $2.09
Ken GriffinCitadel Advisors $-245.1K ExitQ1 2025 $245k $1.85 $2.09
Ken GriffinCitadel Advisors $-63.7K TrimQ4 2024 $64k $1.88 $2.09
Ken GriffinCitadel Advisors $-7.4M TrimQ3 2024 $7M $2.56 $2.09

Insider Trades

Name	Value	Action	Price	Current Price
Hershberg RobertDirector, Officer: See Remarks $28k14.6k shares SellFeb 4, 2025 $1.89 $2.09
Hershberg RobertDirector, Officer: See Remarks $21k11.9k shares SellFeb 11, 2025 $1.76 $2.09
Maltbie ShaneChief Financial Officer $7.7k4.3k shares SellFeb 11, 2025 $1.76 $2.09
Maltbie ShaneChief Financial Officer $7.5k3.9k shares SellFeb 4, 2025 $1.89 $2.09

Trade HLVX

About HilleVax, Inc.

HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent moderate-to-severe acute gastroenteritis resulting from norovirus infections. Its corporate headquarters are located in Boston, Massachusetts.

CEO: Robert M. Hershberg
IPO Date: Apr 29, 2022

Market Data

Open: $2.09
High: $2.09
Low: $2.09
Volume: 2.8M
Avg Volume: 718.7K
52W High: $2.17
52W Low: $1.34

Valuation

Market Cap: $104.8M
Enterprise Value: $69.6M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$109.3M
Revenue: $0
Net Income: -$147.3M
Cash: $154.5M
Debt: $24.5M

Events

EarningsNov 6

EPS est. -0.15 · actual -0.52